SeekingAlpha  Aug 5  Comment 
ArQule (NASDAQ:ARQL) Q2 2014 Earnings Call August 05, 2014 9:00 am ET Executives William B. Boni - Vice President of Investor Relations & Corporate Communications Paolo Pucci - Chief Executive Officer and Director Robert J....
SeekingAlpha  May 7  Comment 
The following audio is from a conference call that will begin on May 07, 2014 at 09:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Benzinga  Apr 14  Comment 
ArQule (NASDAQ: ARQL) shares tumbled 1.08% to touch a new 52-week low of $1.83. ArQule's PEG ratio is -0.77. Charles & Colvard (NASDAQ: CTHR) shares reached a new 52-week low of $2.58. Charles & Colvard shares have dropped 30.87% over the past...
SeekingAlpha  Mar 5  Comment 
Arqule Inc. (ARQL) Q4 2013 Earnings Conference Call March 5, 2014 9:00 am ET Executives Paolo Pucci – Chief Executive Officer Peter Lawrence – President, Chief Operating Officer Brian Schwartz – Chief Medical Officer Rob...
StreetInsider.com  Mar 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/ArQule%2C+Inc.+%28ARQL%29+Posts+Q4+Loss+of+10cShare/9247434.html for the full story.
SeekingAlpha  Feb 8  Comment 
ByPrescient Investment Analysis: ArQule, Inc. (ARQL) is an oncology-focused microcap biotechnology company. A graphical description of its pipeline shows six ongoing clinical trials studying five products. Its shares currently trade for under...
FierceBiotech  Jan 17  Comment 
Massachusetts biotech ArQule has gotten word from its data monitoring committee that its Phase III trial of tivantinib is doing fine despite a dosing reduction that once threatened to derail its development, stoking hopes that the company can...
StreetInsider.com  Jan 17  Comment 
NII Holdings, Inc. (Nasdaq: NIHD) 24.5% HIGHER; announced it will offer Apple's (Nasdaq: AAPL) iPhone 5s, the most forward-thinking smartphone in the world, and iPhone 5c, the most colorful iPhone yet, to Nextel Brazil customers beginning January...
StreetInsider.com  Jan 16  Comment 
Arqule, Inc. (Nasdaq: ARQL) 25.4% HIGHER; The Data Monitoring Committee (DMC) of the METIV-HCC trial has recommended continuation of the ongoing pivotal Phase 3 METIV-HCC trial of tivantinib as a single agent in hepatocellular carcinoma with a...
StreetInsider.com  Jan 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arqule+%28ARQL%29+Reports+DMC+Recommends+Continuation+of+METIV-HCC+Phase+III/9063550.html for the full story.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki